The Latest Cardiac and Vascular News
October 15, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has enrolled the first patient(s) in its U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy. The POWER PAD […]
August 20, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device […]
June 06, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal […]
BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Elizabeth Galle as the company’s new Vice President of Clinical Affairs. She comes to AVS with more than two decades of leadership […]
BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today the opening of its new global headquarters at 451 D Street in Boston, Mass. The new 9,365-square-foot space in the Seaport District will […]
30-year medical device veteran to lead AVS’ operational direction after long tenure with Boston Scientific BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Sean Gilligan as the company’s new Chief Operating Officer. He […]
BioStar Capital led the round with CUE Growth Partners BOSTON, April 4, 2023 – AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B […]
BioStar Capital leads round to accelerate clinical trials and development in peripheral and coronary solutions BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing. The new funding […]
Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels ANN ARBOR, Mich.–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first […]
